Johnson & Johnson (NYSE:JNJ) Shareholders Set to Receive $1.34 Quarterly Dividend

Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Tuesday, October 13th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.34 per share on Tuesday, December 8th. This represents a $5.36 annualized dividend and a yield of 2.2%. The ex-dividend date is Tuesday, November 24th.

Johnson & Johnson has raised its dividend by an average of 0.1% per year over the last three years and has increased its dividend every year for the last 64 years. Johnson & Johnson has a payout ratio of 48.3% meaning its dividend is sufficiently covered by earnings. Analysts expect Johnson & Johnson to earn $12.33 per share next year, which means the company should continue to be able to cover its $5.36 annual dividend with an expected future payout ratio of 43.5%.

Johnson & Johnson Price Performance

NYSE:JNJ traded down $14.83 during trading hours on Tuesday, reaching $248.90. 16,613,205 shares of the company were exchanged, compared to its average volume of 7,994,569. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock’s 50-day moving average is $266.01 and its 200-day moving average is $249.31. The firm has a market cap of $599.83 billion, a PE ratio of 28.84, a price-to-earnings-growth ratio of 2.65 and a beta of 0.21. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period last year, the firm posted $2.80 earnings per share. The company’s revenue was up 5.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 11.18 earnings per share for the current fiscal year.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the business’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 87,569 shares of company stock valued at $23,064,544 over the last three months. 0.16% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in JNJ. Wellington Management Group LLP grew its holdings in shares of Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares during the period. Deutsche Bank AG increased its position in shares of Johnson & Johnson by 8.5% during the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after purchasing an additional 1,225,676 shares during the last quarter. Amundi raised its holdings in Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after buying an additional 2,001,139 shares during the period. Jupiter Topco LLC purchased a new stake in Johnson & Johnson in the 2nd quarter valued at about $1,967,399,000. Finally, Janus Henderson Group PLC lifted its position in Johnson & Johnson by 1.9% in the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after buying an additional 148,497 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.